` 1795 (Lotus Pharmaceutical Co Ltd) vs Taiwan Weighted Index Comparison - Alpha Spread

1795
vs
Taiwan Weighted Index

Over the past 12 months, has underperformed Taiwan Weighted Index, delivering a return of -19% compared to the Taiwan Weighted Index's 2% drop.

Stocks Performance
1795 vs Taiwan Weighted Index

Loading
1795
Taiwan Weighted Index
Add Stock
www.alphaspread.com

Performance Gap
1795 vs Taiwan Weighted Index

Loading
1795
Taiwan Weighted Index
Difference
www.alphaspread.com

Performance By Year
1795 vs Taiwan Weighted Index

Loading
1795
Taiwan Weighted Index
Add Stock

Competitors Performance
Lotus Pharmaceutical Co Ltd vs Peers

Taiwan Weighted Index
1795
LLY
JNJ
NOVO B
ROG
Add Stock

Lotus Pharmaceutical Co Ltd
Glance View

Market Cap
61.8B TWD
Industry
Pharmaceuticals

Lotus Pharmaceutical Co., Ltd., nestled at the intersection of innovation and healthcare, has carved a niche in the competitive pharmaceuticals landscape. Founded in Taiwan, Lotus has evolved into a prominent player, with a strategic focus on the development, manufacturing, and distribution of high-barrier generic drugs and specialty pharmaceuticals. Its journey began as a local pharmaceutical manufacturer but rapidly expanded its horizons through well-timed acquisitions and partnerships. These strategic moves have not only broadened its portfolio but also fortified its foothold in various international markets. The company leverages cutting-edge research and development capabilities to produce cost-effective alternatives to branded medications, which require significant expertise to replicate due to complex manufacturing processes and stringent regulatory requirements. Lotus’s operations hinge on its ability to navigate the intricacies of pharmaceutical regulations and patent landscapes, enabling it to introduce generics as soon as original drug patents expire. This strategic agility allows the company to capture market share quickly and maximize its revenue potential. Lotus Commercializes its products primarily in Asia while also extending its reach to North America and Europe through a network of collaborations and partnerships. Its robust portfolio spans several therapeutic areas, including oncology, central nervous system disorders, and cardiovascular diseases, where the demand for affordable medications is acute. As a result, Lotus not only generates substantial revenue but also plays a pivotal role in enhancing healthcare accessibility and affordability across the globe.

Intrinsic Value
291.98 TWD
Undervaluation 20%
Intrinsic Value
Price
Back to Top